Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Decitabine/Tetrahydrouridine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Decitabine/Tetrahydrouridine: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market.
8 min read
Pentadecapeptide BPC 157(Hudson Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Pentadecapeptide BPC 157(Hudson Biotech): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing.
8 min read
House dust mite allergy immunotherapy(ASIT BioTech SA) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
House dust mite allergy immunotherapy(ASIT BioTech SA): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP.
8 min read
BAT-8008 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
BAT-8008: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
PD-L1 t-haNK(National Cancer Institute) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
PD-L1 t-haNK(National Cancer Institute): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing.
8 min read
Yttrium Y 90-labeled basiliximab(NCI) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Yttrium Y 90-labeled basiliximab(NCI): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals.
8 min read
Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical.
8 min read
Parentide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Parentide: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Tuparstobart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Tuparstobart: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Cytomegalovirus Immune Globulin(pH4)(Shandong Taibang Biological Products) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Cytomegalovirus Immune Globulin(pH4)(Shandong Taibang Biological Products): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers.
8 min read
Allogenic endothelial progenitor cells(Allife Medicine) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Allogenic endothelial progenitor cells(Allife Medicine): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP.
8 min read
LN016 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
LN016: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.